A Phase 3 interventional study of KN3835 in Flexible Hammertoe and Semi-flexible Hammertoe, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to assess the long-term safety of treatment and retreatment with KN3835 for flexible/semi-flexible HMT.
This extension study is for eligible participants who completed parent study KN3835-313 HMT. The study comprises 2 parts:
Endo USA Inc., a Keenova Therapeutics Company is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After observation during Part 1 of the study, participants will have the option to receive treatment or retreatment with KN3835 in Part 2.
Biological: KN3835
Participants will be observed through Part 1. After completion of Part 1, participants will have the option to be observed only during Part 2 of the study.
Participants will receive KN3835 in Part 2 of the Study
Also known as: EN3835
Number of Participants with Adverse Events
Time frame: Observational Day 1 up to Treatment/Retreatment Period Day 360
Change from Baseline In Foot Function Index (FFI) Total Score In Part 1 Observational Period
Time frame: Baseline and up to Observational Day 360
Change from Baseline In FFI Subscales (Difficulty, Pain and Activity Limitation) Scores In Part 1 Observational Period
Time frame: Baseline and up to Observational Day 360
Change from Baseline In Pain Intensity Numeric Rating Scale (NRS) Score In Part 1 Observational Period
Time frame: Baseline and up to Observational Day 360
Percentage of Participants That Meet Retreatment/Treatment Criteria In Part 1 Observational Period
Time frame: Observational Day 180
Percentage of Participants Reporting To Be "Quite Satisfied" and "Very Satisfied" On The Subject Satisfaction With Treatment Scale In Part 1 Observational Period
Time frame: Up to Observational Day 360
Percentage Participants with Investigator Reported "Minimal Improvement", "Much Improvement", or "Very Much Improvement" on the Clinician Global Impression of Change Scale (CGIC) Scale Score in Part 1 Observational Period
Time frame: Up to Observational Day 360
Change from Baseline In Flexion Contracture As Measured By Goniometer in Part 1 Observational Period
Time frame: Baseline and up to Observational Day 360
Percent Change from Baseline In Flexion Contracture As Measured By Goniometer in Part 1 Observational Period
Time frame: Baseline and up to Observational Day 360
Change from Baseline In The Patient Global Impression of Severity (PGIS) HMT Overall Scale Score in Part 1 Observational Period
Time frame: Baseline and up to Observational Day 360
Percentage Of Participants reporting "Minimal Improvement", "Much Improvement", or "Very Much Improvement" on the Patient Global Impression of Change Scale (PGIC) HMT Overall Scale Score in Part 1 Observational Period
Time frame: Up to Observational Day 360
Change from Baseline In FFI Total Score In Part 2 Treatment/Retreatment Period
Time frame: Baseline and up to Treatment/Retreatment Period Day 360
Change from Baseline In FFI Subscales (Difficulty, Pain and Activity Limitation) Scores In Part 2 Treatment/Retreatment Period
Time frame: Baseline and up to Treatment/Retreatment Period Day 360
Change from Baseline In Pain Intensity NRS Score In Part 2 Treatment/Retreatment Period
Time frame: Baseline and up to Treatment/Retreatment Period Day 360
Percentage of Participants Reporting To Be "Satisfied" and "Very Satisfied" On The Subject Satisfaction With Treatment Scale In Part 2 Treatment/Retreatment Period
Time frame: Up to Treatment/Retreatment Period Day 360
Percentage Of Participants with Investigator Reported "Minimal Improvement", "Much Improvement", or "Very Much Improvement" on the CGIC HMT Overall Scale Score in Part 2 Treatment/Retreatment Period
Time frame: Up to Treatment/Retreatment Period Day 360
Change from Baseline In Flexion Contracture As Measured By Goniometer in Part 2 Treatment/Retreatment Period
Time frame: Baseline and up to Treatment/Retreatment Period Day 360
Percent Change from Baseline In Flexion Contracture As Measured By Goniometer in Part 2 Treatment/Retreatment Period
Time frame: Baseline and up to Treatment/Retreatment Period Day 360
Change from Baseline In The PGIS HMT Overall Scale Score in Part 2 Treatment/Retreatment Period
Time frame: Baseline and up to Treatment/Retreatment Period Day 360
Percentage Of Participants reporting "Minimal Improvement", "Much Improvement", or "Very Much Improvement" on the PGIC HMT Overall Scale Score in Part 2 Treatment/Retreatment Period
Time frame: Up to Treatment/Retreatment Period Day 360
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase
Endo USA Inc., a Keenova Therapeutics Company →